Zhejiang Medicine Co Ltd (SHG:600216) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Medicine Co Ltd (600216)
Zhejiang Medicine Co Ltd (SHG:600216) has a market capitalization of $2.02 Billion (CN¥13.78 Billion) as of May 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #6276 globally and #1392 in its home market, demonstrating a -2.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Medicine Co Ltd's stock price CN¥14.33 by its total outstanding shares 961637750 (961.64 Million). Analyse 600216 cash flow conversion to see how efficiently the company converts income to cash.
Zhejiang Medicine Co Ltd Market Cap History: 2015 to 2026
Zhejiang Medicine Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.50 Billion to $2.02 Billion (4.40% CAGR).
Index Memberships
Zhejiang Medicine Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Shanghai Shenzhen CSI 300
CSI300
|
$4.20 Trillion | 0.05% | #216 of 285 |
Weight: Zhejiang Medicine Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Zhejiang Medicine Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Medicine Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.24x
Zhejiang Medicine Co Ltd's market cap is 0.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.92x
Zhejiang Medicine Co Ltd's market cap is 1.92 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.50 Billion | $4.50 Billion | $161.80 Million | 0.33x | 9.30x |
| 2016 | $1.55 Billion | $5.28 Billion | $450.10 Million | 0.29x | 3.44x |
| 2017 | $1.67 Billion | $5.69 Billion | $253.15 Million | 0.29x | 6.58x |
| 2018 | $1.08 Billion | $6.86 Billion | $364.55 Million | 0.16x | 2.97x |
| 2019 | $1.69 Billion | $7.04 Billion | $342.77 Million | 0.24x | 4.93x |
| 2020 | $1.82 Billion | $7.33 Billion | $717.40 Million | 0.25x | 2.53x |
| 2021 | $2.31 Billion | $9.13 Billion | $1.05 Billion | 0.25x | 2.21x |
| 2022 | $1.62 Billion | $8.12 Billion | $539.57 Million | 0.20x | 3.00x |
| 2023 | $1.51 Billion | $7.79 Billion | $429.64 Million | 0.19x | 3.51x |
| 2024 | $2.23 Billion | $9.38 Billion | $1.16 Billion | 0.24x | 1.92x |
Competitor Companies of 600216 by Market Capitalization
Companies near Zhejiang Medicine Co Ltd in the global market cap rankings as of May 7, 2026.
Key companies related to Zhejiang Medicine Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #501 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #530 globally with a market cap of $50.06 Billion USD ( CN¥342.11 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #541 globally with a market cap of $49.01 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #574 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #501 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.06 Billion | CN¥53.63 |
| #541 | Zoetis Inc | NYSE:ZTS | $49.01 Billion | $111.22 |
| #574 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $43.83 |
Zhejiang Medicine Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Zhejiang Medicine Co Ltd's market cap moved from $1.50 Billion to $ 2.02 Billion, with a yearly change of 4.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.02 Billion | +3.39% |
| 2025 | CN¥1.95 Billion | -12.61% |
| 2024 | CN¥2.23 Billion | +47.81% |
| 2023 | CN¥1.51 Billion | -6.79% |
| 2022 | CN¥1.62 Billion | -29.96% |
| 2021 | CN¥2.31 Billion | +27.37% |
| 2020 | CN¥1.82 Billion | +7.46% |
| 2019 | CN¥1.69 Billion | +56.04% |
| 2018 | CN¥1.08 Billion | -35.01% |
| 2017 | CN¥1.67 Billion | +7.63% |
| 2016 | CN¥1.55 Billion | +2.87% |
| 2015 | CN¥1.50 Billion | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of Zhejiang Medicine Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.02 Billion USD |
| MoneyControl | $2.02 Billion USD |
| MarketWatch | $2.02 Billion USD |
| marketcap.company | $2.02 Billion USD |
| Reuters | $2.02 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Medicine Co Ltd
Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and medical products in China and internationally. The company offers synthetic vitamin E, natural vitamin E, ß-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also provides fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition produ… Read more